Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion